LEGACy

Gastric cancer is the third leading cause of cancer death in both sexes worldwide and no strategies have improved prognosis in locally advanced gastric cancer. An increase in the survival rate for patients with gastric cancer is expected to come from a personalised medicine approach. So far, gastric cancer treatments such as surgery, radiotherapy, chemotherapy and immunotherapy have been used. While these treatments might work for one person, this does not mean they will work for another, despite the possible side-effects.

Through personalised medicine, gastric cancer treatment is chosen based on who the patient is, instead of the type of tumour, leading to an improved prognosis of gastric cancer. LEGACy will use a personalised approach that will improve gastric cancer treatment by improving the knowledge of which treatment will work best for each patient. Additionally, the project will identify and educate those with higher risk of getting gastric cancer earlier and improve the early detection of gastric cancer when the prognosis is still higher.

ECPC leads the project’s work on communication and dissemination, ensuring an effective external stakeholder network and the engagement of patients and the public. ECPC developed and maintains a project website and multiple social media platforms, and disseminates a triannual newsletter and press releases. ECPC is also responsible for patient information, reviewing informed consent forms, involving expert patient advocates in the online training courses, and hosting a final stakeholder event at the completion of the project.